The intracellular renin-angiotensin system in the heart

  title={The intracellular renin-angiotensin system in the heart},
  author={Rakesh Kumar and Vivek P. Singh and Kenneth M. Baker},
  journal={Current Hypertension Reports},
Recently, several novel aspects of the renin-angiotensin system (RAS) were described, which potentially may change the therapeutic strategy to treat cardiovascular disease, in addition to enhancing understanding of this system’s mechanism of action. Most notably, identification of a functional intracellular RAS may address several unanswered questions regarding a direct role of angiotensin (Ang) II in cardiac remodeling and incomplete efficacy of angiotensin-converting enzyme inhibitors and… 

Intracardiac intracellular angiotensin system in diabetes.

Evidence supporting an intracellular RAS in different cell types, ANG II's actions in cardiac cells, and its mechanism of action are reviewed, focusing on the intraceocytes of the renin-angiotensin system in diabetes.

Knocking Out Angiotensin II in the Heart

Current and emerging approaches towards inhibiting cardiac RAS function in order to further improve cardiovascular disease outcomes are discussed.

The intracrine renin-angiotensin system.

The RAS seems relevant at the cellular level, wherein individual cells have a complete system, termed the intracellular RAS, and from cells to tissues to the entire organism, the RAS exhibits continuity while maintaining independent control at different levels.

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

Findings published in the last 15 years on the structure, pharmacology, signaling, physiology, and disease states related to angiotensin receptors are summarized.

The Impact of microRNAs in Renin–Angiotensin-System-Induced Cardiac Remodelling

The aim of this review is to summarize the current knowledge in the field that is still in the early stage of preclinical investigation with occasionally conflicting reports and to understand the big picture of microRNAs which aids in the improved understanding of cardiac response to injury.

An evolving story of angiotensin-II-forming pathways in rodents and humans.

The present review summarizes the progress that has been made in the novel exploration of intermediate shorter forms of angiotensinogen through the characterization of the expression and functions of the dodecapeptide Ang-(1-12) [angiotens in-( 1-12)] in the cardiac production of AngII.

Activation of the Human Angiotensin-(1-12)-Chymase Pathway in Rats With Human Angiotensinogen Gene Transcripts

It is concluded that this humanized model of angiotensinogen-dependent hypertension expresses the human sequence of Ang-(1-12) in plasma and cardiac tissue and responds to blockade of AT1-R with further increases in the human form of cardiac Ang-( 1-12).

Intracellular renin-angiotensin signaling: working from the inside-out in hypothalamic neurons. Focus on "Direct evidence of intracrine angiotensin II signaling in neurons".

  • R. Wondergem
  • Biology
    American journal of physiology. Cell physiology
  • 2014
the renin-angiotensin system (RAS) has been one of the most extensively studied endocrine control systems in humans. It harks back to the discovery by Tigerstedt and Bergman in 1898 that renin, a

Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture

RAS inhibition by losartan or perindopril prevented cardiac rupture at the acute phase of MI through blockade of splenic release of monocytes and neutrophils and consequently attenuation of systemic and regional inflammatory responses.



The intracellular renin–angiotensin system: a new paradigm

The intracellular renin–angiotensin system: implications in cardiovascular remodeling

Alternative mechanisms of angiotensin II synthesis and action suggest a need for novel therapeutic agents to block the intracellular renin–angiotens in system.

Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?

A critical assessment of the results of clinical trials of ACE inhibitors and ARBs across a variety of clinical conditions and the potential need for new methods for blocking the renin system, including the use of renin inhibitors is assessed.

Circulating versus tissue renin-angiotensin system: On the origin of (pro)renin

An update on the sources of (pro)renin in the body is provided, the known stimulants and inhibitors of its production are listed, and the concept that prorenin rather than renin determines tissue angiotensin generation is discussed.

Cardiac and Vascular Renin-Angiotensin Systems

Clinical, animal, and cell culture studies support the concept that these local RASs can act in an autocrine, paracrine, and/or intracrine manner.

Diversity of pathways for intracellular angiotensin II synthesis

There is significant diversity in the mechanism of intracellular synthesis of Ang II in various cell types and pathological conditions, and observations suggest that a therapeutic intervention to block the RAS should take into consideration the nature of the disorder and the cell type involved.

Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system.

These mice develop myocardial hypertrophy without signs of fibrosis independently from the presence of hypertension, demonstrating that local Ang II production is important in mediating the hypertrophic response in vivo.

Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice

These findings are the first to distinguish between local and systemic effects of angiotensin II on the heart and introduce a novel technique for studying tissue-specific peptide function.

Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney

The findings demonstrate the critical role of the kidney in the pathogenesis of hypertension and its cardiovascular complications and suggest that the major mechanism of action of RAS inhibitors in hypertension is attenuation of angiotensin II effects in the kidney.

Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.

It is demonstrated that regulation of blood pressure by extrarenal AT(1A) receptors cannot be explained by altered aldosterone generation, which suggests that AT( 1) receptor actions in systemic tissues such as the vascular and/or the central nervous systems make nonredundant contributions to blood pressure regulation.